For the treatment of AD, an interesting multi-modal drug profile would be a compound that simultaneously acts as an AChE inhibitor and a positive allosteric modulator (PAM) at one of the pro-cognitive nicotinic acetylcholine receptors (nAChR), especially the α7 or α4β2 subtype. The gene discussed is CHRNA4; the disease is Alzheimer disease.